tbuckley/cabot-search huggingface dataset:
932P Accuracy and prognostic implications of extranodal extension on radiologic imaging in HPV-positive oropharyngeal cancer (HNCIG-ENE): A multinational, real-world study
Authors: H. Mehanna, A. Abou-Foul, C. Henson, C. Kristunas, L. McDowell, C. von Buchwald, W. Lydiatt, B. Branstetter, J. Klussmann, B. Wollenberg, M. Broglie, R. Prestwich, H. Mirghani, S. Krishnan, S. Yom, P. Nankivell, M. Oliva Bernal, M. van den Brekel, R. Leemans
Journal: Annals of Oncology (2024)
926P Genetic alteration in olfactory neuroblastoma: Unraveling carcinogenesis mechanisms and chemotherapy resistance through whole exome sequencing analysis
Authors: H. Furukawa, T. Shimoi, T. Mori, Y. Honma, E. Noguchi, H.S. Okuma, Y. Kojima, K. Yonemori
Journal: Annals of Oncology (2024)
1221P Stereotactic ablative radiotherapy in combination with nivolumab for early stage operable non-small cell lung cancer: A phase II study
Authors: G. Schvartsman, Y. Amarato, G. Prado dos Santos, D. Bugano Diniz Gomes, L.D.O. Koch, B. Bibas, O. Gomes, P. Vidal Campregher, P. Severino, L. Cavalheiro Marti, V. Paes Ribeiro, L. Leaden, R. Caruso Chate, J. Ribas Milanez de Campos, V.A. Ramos Sousa, P. Taranto, F.S. Moura, R.M. Terra, A.C.P.D. Rezende, M. Naoyuki Samano
Journal: Annals of Oncology (2024)
907P Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Authors: D. Soulieres, C. Le Tourneau, J-P. Machiels, B. Burtness, K.J. Harrington, J. Shen, J. Tao, A. Webber, A. Vajdi, A. Loboda, N. Lerman, B. Gumuscu, L.F.L. Licitra
Journal: Annals of Oncology (2024)
851MO Final analysis of a phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck (JCOG1008)
Authors: M. Tahara, N. Kiyota, H. Fujii, Y. Asada, H. Mitani, Y. Hirayama, N. Nishio, Y. Onozawa, N. Hanai, A. Ohkoshi, N. Monden, M. Nagaoka, S. Minami, T. Fujii, K. Tanaka, S. Yoshimoto, T. Kodaira, J. Mizusawa, K. Nakamura, R. Hayashi
Journal: Annals of Oncology (2024)
863P Safety and efficacy of four courses of pembrolizumab combined with carboplatin and albumin-binding paclitaxel versus two courses of neoadjuvant therapy in patients with resectable head and neck squamous cell carcinoma: An optimal efficacy study (prospective, two-arm, phase II)
Authors: J. Li, H. Cao, J. Liu, Q. Li, S. Xie, L. Wang, T. Lan, Y. Wang, Z. Lin, X. Duan, J. Li, Y. Li
Journal: Annals of Oncology (2024)
889P Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A prospective, single-arm, phase II trial
Authors: M. Li, S. Qu, G. Lan, M. Shi, Y. Wang, M. Ban, J. Weng, J. Wei, W. Huang, Z. Gui, X. Mao, X. Huang, S. Xie, H. Wang, B. Huang, Y. Qin
Journal: Annals of Oncology (2024)
912P Selection of personalized salvage treatments in advanced refractory head and neck squamous cell carcinomas via multi-omics tumor profiling
Authors: R. Ajami, A. Shreenivas, S. Limaye, D.S. Patil, N. Shrivastava, V. Mhase, S.B. Patil, V. Datta, R. Datar
Journal: Annals of Oncology (2024)
891P Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer: The POINT study
Authors: C. Gurizzan, S. Farinatti, A. Alberti, P. Bonomo, C. Resteghini, S. Alfieri, C. Bergamini, F. Perri, G. Moretti, D. Galizia, M. Cossu Rocca, A.P. Sponghini, S. Secondino, M. Zamparini, L. Lorini, P. Bossi
Journal: Annals of Oncology (2024)
901P A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin therapy followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma
Authors: S. Park, H.A. Jung, S-H. Lee, J. Cho, K. Yang, D. Oh, Y.C. Ahn, E-H. Kim, N. Choi, H-S. Jeong, M-J. Ahn
Journal: Annals of Oncology (2024)
874P Preliminary outcomes from a phase Ib/II study of WX390 combined with toripalimab in patients with recurrent or metastatic head and neck squamous cell carcinoma
Authors: Y. Guo, L. Xue, W. Tang, B. Li, Z. zhu, Y. Ding, L. Niu, Y. Jia, X. Jia, Y. Qi, Y. Li
Journal: Annals of Oncology (2024)
1240MO Quantitative radiomics for the detection of symptomatic pneumonitis following chemoradiotherapy in patients with stage III unresectable NSCLC
Authors: J. Naidoo, V.D. Haakensen, J. Bar, F. Belmans, A. Corsi, M. Flechet, L. Libert, C.C. Meca, N. Tsoutzidis, P. Chander, K.A. Patwardhan, J. Faria, D. De Ruysscher
Journal: Annals of Oncology (2024)
1268P Concordances assessment between MET-positive circulating tumour cells and disease progression in patients with EGFR mutated NSCLC
Authors: J. Park, N.Y. Kim, J. Kim, E. Oh, J-H. Nam, H.Y. Kim, H-E. Kim, H. Choi, J. Choi, Y.K. Shin, S-H. Lee
Journal: Annals of Oncology (2024)
915P Longer OS and RFS for CD3high/PD-L1+ head and neck squamous cell carcinoma (HNSCC) patients
Authors: S. Laban, R. Remark, C. Idel, J. Ribbat-Idel, R. Krupar, A. Schröck, N. Klümper, J. Döscher, A.G. Sikora, T. Abou Kors, A. von Witzleben, J. Vahl, A. Grages, M. Sonntag, C. Brunner, T.K. Hoffmann, S. Gnjatic
Journal: Annals of Oncology (2024)
853MO Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head &amp; neck: Results of a randomized, double-blind phase II trial
Authors: J. Fayette, G. Thomas, A. Daste, M. Rotarski, B. Castelo, A. Rullan, A. Levine, R.S. Philipson, K.J. Harrington
Journal: Annals of Oncology (2024)
1208MO Phase III trial of perioperative pirfenidone therapy for lung cancer with idiopathic pulmonary fibrosis (IPF): NEJ034 study
Authors: Y. Goto, Y. Sakairi, I. Yoshino, H. Suzuki, M. Okada, Y. Sato, M. Tsuboi, T. Nakagawa, T. Iwata, J. Okami, H. Takei, H. Suzuki, N. Ikeda, Y. Sato, K. Kobayashi
Journal: Annals of Oncology (2024)
1227P Update on the analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1
Authors: M. Sereno, A. Collazo-Lorduy, J. Baena Espinar, S. Falagán Martínez, C. Aguado de la Rosa, P. Cruz Castellanos, L.E. Chara Velarde, R. López-Castro, A. López-Martin, J. Rubio Perez, A. Gomez Rueda, C. Traseira Puchol, X. Mielgo Rubio, B. Losada Vila, J. Rogado, D. Gómez de Antonio, E. Bernal Hertfelder, L. Gutierrez Sainz, G. Rubio Romero
Journal: Annals of Oncology (2024)
879P VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Authors: J. Weiss, J. Kaczmar, K.J. Harrington, R. Mehra, F. Worden, R. Zinner, A. Giri, H. Kang, S. Najeeb, T. Panella, A. Sukari, C. Grant, V. Kaur, S. Jones, D. Schaaf, K. Price
Journal: Annals of Oncology (2024)
1248P Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: LAURA China cohort analysis
Authors: X. Dong, H. Jian, M. Huang, S. Yuan, Z. Zhu, L. Wu, M. Chen, N. Bi, Y. Pan, Y. Wang, D. Lv, E. Armenteros Monterroso, X. Huang, J. Liu, W. Fu, Y. Zhao, S. Lu
Journal: Annals of Oncology (2024)
855P Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study
Authors: C. Toullec, S. Seo, A.G. Robinson, H-H. Chou, P. Salman, F. Ghiringhelli, O. Ozyilkan, C.I. Rojas, M.A.N. Sendur, C. Le Tourneau, C.J. Yen, S. Aksoy, S. Ochsenreither, E.P. Yanez Ruiz, S.Y. Rha, R. Shapira-Frommer, Q. Liu, M. Du Plessis, T. Keenan, C-H. Hsu
Journal: Annals of Oncology (2024)
1259MO Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)
Authors: D. Planchard, J. Mazieres, C. Mascaux, F. Guisier, P. Tomasini, M. Wislez, D. Moro-Sibilot, S. Cousin, A.B. Cortot, S. Couraud, V. Fallet, C. Guguen, A. Lagrange, A-C. Madroszyk Flandin, J. Otto, M. Pérol, B. Roch, E. Amour, F. Morin, C. Ricordel
Journal: Annals of Oncology (2024)
868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Authors: W. Wong, D.R. Adkins, J.G. Misleh, J. Lorch, J.S. Grewal, J. Russell, J. Cetnar, A.L. Ho, K. Chen, K. Aysola, J. Thomas
Journal: Annals of Oncology (2024)
1236P ctDNA-Lung-Detect: Profiling of non-shedding ctDNA early stage resected non-small cell lung cancers
Authors: S. Khan, J. Feng, T.K. Waddell, K. Yasufuku, A. Pierre, S. Keshavjee, J. Yeung, M. Cypel, L. Donahoe, E. Wakem, M. de Perrot, A. Salvarrey, N. Safieddine, M. Ko, D. Parente, M. Rabey, L. Le, C. Pipinikas, A. Chevalier, N.B. Leighl
Journal: Annals of Oncology (2024)
1173P Combining mass spectrometry with quantitative continuous scoring to unlock the full quantitative potential of immunohistochemistry
Authors: A. Hidalgo-Sastre, J. Zaucha, N. Damond, T.H. Tan, A. Meier, M. Schick, M. Korade, A. Kunihiro, A. Chambers, N. Durham, J.C. Barrett, G. Schmidt, H. Sade, Y.J. Kim, M. Gustavson, J.S. Reis-Filho, M.C. Rebelatto, N. Giraldo
Journal: Annals of Oncology (2024)
1210P Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study
Authors: M.C. Garassino, S. Gao, M. Liberman, J.D. Spicer, K. Chen, T. Vanakesa, L. Thiberville, F.D.F. Chaves, G. Liu, M. Okada, H. Saji, K. Laktionov, A. Rittmeyer, J. Bosch-Barrera, R.D. Gentzler, A.K. Ganti, E. Jensen, S.M. Keller, A. Samkari, H. Wakelee
Journal: Annals of Oncology (2024)
1154P Prospective multinational evaluation of alkylating-induced hypermutation in neuroendocrine neoplasms (NEN): Clinical and molecular profiles associated with response to immune checkpoint inhibitors (CPI)
Authors: E. Trevisani, S. Cingarlini, R. Gomes Taboada, M. Borghesani, T.C. Felismino, V.S.E. Silva, A. Reni, C. Luchini, G. Torrezan, A. Mafficini, M. Milella, A. Scarpa, R. Riechelmann
Journal: Annals of Oncology (2024)
860P Pembrolizumab in combination with low-dose cisplatin/5-fluorouracil for neoadjuvant chemoimmunotherapy of locally advanced head and neck squamous cell carcinoma: A single-arm clinical trial
Authors: J. Xu, Y. Zhang, C. Shao, K. Chen, H. Guo, H. Jiang, A. Bi, D. Lu, J. Wang, L. Jiang, G. Ru, X. He, Z. Wang, L. Wang, G. Zheng, P. Huang, Y. Duan, Z. Tan, C. Zheng, M. Ge
Journal: Annals of Oncology (2024)
1179P WomEC: a novel diagnostic test for the detection of endometrial cancer in uterine fluids
Authors: A. Gil-Moreno, J. Carvajal, E. Coll de la Rubia, A. Garcia, M. Rigau, E. Martinez, I. Campoy, M.Á. Casares de Cal, A. Gomez Tato, J. Castellvi, A. Luzarraga Aznar, M. Marti, M. Cedo, G. Dittmar, S. Cabrera, E. Colas
Journal: Annals of Oncology (2024)
857P Safety and efficacy of neoadjuvant immunochemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial
Authors: J. Yan, K. Wang, M. Yang, Y-J. Gu, X. Dou, N. Zhou, L. Xiang, J. Chen, L. Nie, H. Chen, B. Huang, Y. Zhu, H. Sha, J. Zhu, C. Zhu, X. Zhang, D. Chen, X-H. Shen, X-Y. Qian
Journal: Annals of Oncology (2024)
1146MO Interim analysis of CABONEN: A multicenter phase II trial investigating cabozantinib in patients with advanced, low proliferative NEN G3
Authors: A.O. Koenig, J. Reinecke, J. Halfen, K. Lang, U. König, R. Tostmann, N. Kirchhof, T. Asendorf, D. Hörsch, A. Kröcher, M. Quante, V. Ellenrieder, N. Schulte, T. Wirth, A. Weich, L. Apostolidis, S. Krug, A. Rinke, M.E. Pavel
Journal: Annals of Oncology (2024)
783P ESCAT gene actionability detection in early-stage ovarian: A descriptive analysis of an Italian referral center
Authors: F. Camarda, L. Mastrantoni, C. Nero, S. Duranti, I. Marino, R. Trozzi, V. Iacobelli, A. Minucci, F. Giacomini, L. Giacò, M. Karimi, A. Preziosi, G. Maneri, T. Pasciuto, A. Fagotti, G. Scambia
Journal: Annals of Oncology (2024)
819P Efficacy and safety of orelabrutinib plus R-CHOP-like regimens for treatment-naïve diffuse large B-cell lymphoma with double expression
Authors: W. Wan, X. Zhang, P. Yang, W. Zhao, S. Li, F. Bao, Y. Li, L. Ma, H-M. Jing
Journal: Annals of Oncology (2024)
1241MO Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the phase III LAURA study
Authors: S. Lu, M-J. Ahn, T.R. Baisamut, M. Ozguroglu, T. Kato, J.C-H. Yang, M. Huang, F.K. Fujiki, T. Inoue, V.Q. Le, V. Sriuranpong, D. Vicente, C.S. Fuentes, R.N. Darapureddi, L. Poole, E. Armenteros Monterroso, T. van der Gronde, Y. Rukazenkov, S.S. Ramalingam
Journal: Annals of Oncology (2024)
1212P IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 TC≥50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)
Authors: E. Felip, E. Vallieres, O. Gologordko, A. Martinez-Marti, C. Zhou, N.K. Altorki, A. Rittmeyer, A. Chella, M. Reck, W. Schütte, M. Okada, R. Liersch, M.E. Teixeira, E. Bennett, B.J. Gitlitz, M. Srivastava, M. Ballinger, C. Zhu, L. Crama, H. Wakelee
Journal: Annals of Oncology (2024)
1177P FRESH: The Gustave Roussy program to facilitate access to liquid biopsy for precision oncology in France
Authors: E. Rouleau, M. Morfouace, S. Taleb, M. Sakkal, M. Aldea, A. Hollebecque, B. Verret, V. Suybeng, A. Bayle, L. Lacroix, S. Michiels, E. Angevin, F. André, B. Besse, C.P. Massard, F. Barlesi, A. Italiano
Journal: Annals of Oncology (2024)
578P Increased therapeutic index of muzastotug (ADG126), a masked anti-CTLA-4 antibody, in combination with pembrolizumab (pembro) enables significant clinical benefits and supports further clinical development in patients with metastatic MSS CRC
Authors: D. Li, S.Y. Kim, H.K. Kim, S. Sharma, S.J. Shin, J. Lee, S-A. Im, X.K. She, Y. Li, L.E.C. Chung, P. Xiao, G. Liu, S. Zeng, D. HuLowe, M. Chisamore, P.P. Luo, J. Zha, M.R. Patel
Journal: Annals of Oncology (2024)
499TiP A phase II study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy
Authors: B. Stockdale, S. Bertrand, E. Villanueva, L. Naya, A. Lyng, B. Berman, V.K. Vishnudas, M.A. Kiebish, S. Gesta, P.K. Tekumalla, N.R. Narain, L. Recht, V. Modur, S. Nagpal
Journal: Annals of Oncology (2024)
553P Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
Authors: J. NAGATA, Y. Nakamura, J. Watanabe, N. Akazawa, M. Ikeda, M. Yokota, K. Kato, M. Kotaka, K. Yamazaki, Y. Kagawa, K-H. Yeh, G. Laliotis, A. Jurdi, D. Kotani, H. Bando, H. Taniguchi, I. Takemasa, T. Kato, T. Yoshino, E. Oki
Journal: Annals of Oncology (2024)
485P A spatio-temporal evolution mathematical model of glioma growth: The influence of cellular and nutrient interactions on the tumor microenvironment
Authors: K. Borges, G. Almeida, B.V.R.E. Almeida, E. Macêdo, J.N. Quaresma, A.M. Tolentino, C. Borges Junior, C.E. Costa, R. Cotta
Journal: Annals of Oncology (2024)
535P Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience
Authors: A. Boccaccino, M. Frapoli, D. Rossini, L. Salvatore, A. Passardi, G. Papiani, A.A. Valsecchi, A. Puccini, G. Massaro, S. Santucci, A. Guidolin, A. Spring, E. Romagnani, S. Tamberi
Journal: Annals of Oncology (2024)
567P Interim endoscopic restaging after induction chemotherapy to predict complete response and survival after total neoadjuvant therapy in low rectal cancer: Ad-hoc analysis of the IMPACT trial
Authors: E. Shinozaki, H. Osumi, A. Chino, T. Akiyoshi, S. Taguchi, A. Ooki, S. Udagawa, S. Fukuoka, T. Wakatsuki, M. Ogura, K. Chin, S. Matsui, T. Mukai, T. Yamaguchi, N. Miyazaki, Y. Fukunaga, K. Yamaguchi, T. Konishi
Journal: Annals of Oncology (2024)
526P Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age
Authors: M.E. Elez Fernandez, N.A. Dasari, S. Lonardi, C. Eng, R. Garcia-Carbonero, T. Yoshino, A. Sobrero, J.C. Yao, P. García Alfonso, J. Kocsis, A. Cubillo Gracian, A. Sartore Bianchi, T. Satoh, V. Randrian, C. Cremolini, Z. Yang, W. Schelman, H. Zhu, L. Chen, J. Tabernero
Journal: Annals of Oncology (2024)
512O Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial
Authors: U. Güller, S. Hayoz, D. Horber, S. De Dosso, D. Koeberle, S. Schacher Kaufmann, R.I. Inauen, M. Stahl, T. Delaunoit, T.J. Ettrich, G.M. Bodoky, P. Michel, T. Kössler, K. Rothgiesser, S. Calmonte, M. Joerger
Journal: Annals of Oncology (2024)
525P Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody
Authors: K. Sugiyama, H. Yasui, M. Nakamura, T. Sagawa, T. Kawai, K. Kataoka, D. Manaka, N. Akazawa, T. Okuno, T. Shimura, M. Shiozawa, Y. Sunakawa, H. Ota, M. Kotaka, H. Okuyama, Y. Okita, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji
Journal: Annals of Oncology (2024)
486P Effects of a BBB-penetrating oligonucleotide drug, RBD8088, in mouse models of human glioblastoma
Authors: J. Grönros, S. Li, M. Ba, Z. Wang, L. Cao, M. Zhang, X. Ji, Z. Guo, H. Zhang, S. Gao, Z. Liang, L-M. Gan
Journal: Annals of Oncology (2024)
523P A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)
Authors: M. Wakabayashi, H. Taniguchi, S. Yuki, H. Takeda, S. Mitani, Y. Okumura, N. Akazawa, A. Makiyama, T. Kudo, C. Kudo, K. Mori, K. Muro
Journal: Annals of Oncology (2024)
565P Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Authors: C.J. Brown, C. O'Callaghan, J.M. Loree, H. Moloo, R. Auer, D. Jonker, M. Raval, G. Ma, A. Caycedo-Marulanda, V. Simianu, S. Patel, L. Pitre, R. Helewa, V.L. Gordon, K. Neumann, D. Bosse, M.J. Krahn, D. Tu, H. Kennecke
Journal: Annals of Oncology (2024)
574P First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study
Authors: Z.Y. Lin, H. Ma, X. Liang, L. Zhao, D. Yu, J. Xue, S. Yang, J. Hu, J. Liu, D. Zhang, Z. Yin, M. Yuan, L. Zhao, H. Wang, C. Wei, L. Ding, Y. Chen, H. Zhou, T. Zhang
Journal: Annals of Oncology (2024)
515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)
Authors: J. Tabernero, T. Yoshino, T.W. Kim, R. Yaeger, J. Desai, H.S. Wasan, E. Van Cutsem, F. Ciardiello, T. Maughan, C. Eng, J. Tie, M.E. Elez Fernandez, S. Lonardi, T. Usari, E. Hahn, S. Dychter, G. Ferrier, X. Zhang, S. Kopetz
Journal: Annals of Oncology (2024)
530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
Authors: A. Seeber, F. Huemer, B. Doleschal, H. Taghizadeh, P. Reimann, F. Moik, S. Kostmann, L. Wagner, J. Granitzer, M. Abdel Hamid, C. Bachleitner, A. Amann, D. Wolf, R. Greil, P.J. Jost, T. Winder, H. Rumpold, L. Weiss, A. Gerger, J.M. Riedl
Journal: Annals of Oncology (2024)
522P Impact of age and single heterozygous UGT1A1 on the safety and efficacy of first-line FOLFIRI or FOLFOXIRI in combination with ramucirumab (RAM) for metastatic colorectal cancer (mCRC): Subgroup analyses of WJOG9216G (RECAST)
Authors: K. Shiraishi, Y. Kito, H. Shoji, T. Yamada, T. Tsushima, S. Mitani, H. Yasui, H. Hara, K. Shimozaki, T. Esaki, Y. Shinohara, T. Tsuzuki, S. Kajiura, N. Izawa, K. Murata, K. Yoshimura, H. Kawakami, S. Hironaka, K. Yamazaki, K. Muro
Journal: Annals of Oncology (2024)
472P Comprehensive quinomics assessment of BPM31510IV treatment in advanced glioblastoma multiforme patients
Authors: S. Nagpal, J.J. Henao, B. Greenwood, S. Karmacharya, M-D. Nastke, S. Gesta, N.R. Narain, V. Modur, M.A. Kiebish, L. Recht
Journal: Annals of Oncology (2024)
445MO Dual inhibition of post-radiogenic angio-vasculogenesis in glioblastoma: Results of the phase I/II GLORIA trial
Authors: F.A. Giordano, J.P. Layer, L.L. Friker, R. Turiello, T. Zeyen, B. Pregler, O. Mirallas, S. Kebir, M. Renovanz, P. Hambsch, T. Pietsch, E. Gkika, M. Platten, M. Schneider, O. Grauer, G. Tabatabai, M. Glas, C. Seidel, U. Herrlinger, M. Hölzel
Journal: Annals of Oncology (2024)
564P Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Authors: F. Xia, Y. Chen, Y. Wang, H. Zhang, J. Wan, L. Shen, Y. Wang, W. Yang, M. Zhou, R. Wu, Y. Bai, D. Zhou, J. Li, S. Cai, X. Li, Z. Zhang
Journal: Annals of Oncology (2024)
580P Impact of RAS and BRAFV600E mutations on tumor immune microenvironment and associated genomic alterations in patients with microsatellite instability (MSI) or DNA mismatch repair deficient (dMMR) colorectal cancers
Authors: A. Puccini, D. Foureau, E. Mauer, T. André, W. Zhang, S.M. El-Refai, T.J. George, J. Tabernero, F.A. Sinicrope, J. Tie, S. Kopetz, E. Van Cutsem, S. Lonardi, M.J. Overman, M.E. Salem
Journal: Annals of Oncology (2024)
573P M9140, an anti-CEACAM5 antibody drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): Updated results from a phase I trial
Authors: V. Boni, S. Kopetz, K. Kato, K. Raghav, M. Vieito, A.G. Pallis, C. Habermehl, I.I. Rodriguez Rivera
Journal: Annals of Oncology (2024)
558P Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Authors: K. Kataoka, K. Mori, Y. Nakamura, J. Watanabe, K. Hirata, N. Akazawa, M. Yokota, K. Kato, M. Kotaka, K. Yamazaki, Y. Kagawa, S. Sharma, A. Jurdi, D. Kotani, H. Bando, H. Taniguchi, I. Takemasa, T. Kato, T. Yoshino, E. Oki
Journal: Annals of Oncology (2024)
563P Preliminary analysis in Protector-C study: A prospective, multicenter cohort of utilizing circulating tumor DNA (ctDNA) methylation as postoperative surveillance for colorectal cancer (CRC)
Authors: Z. Liu, W. Zhang, G. Chen, G. Wang, Y. Chen, Z. Wang, H. Liu, G. Yu, Y. Zhang, J. Dai, Z. Yuan, H. Hu, L. Zhou, Y. Li, P. Sun, Q. Wu, H. Jia, H. Wang, R. Liu, X. Wang
Journal: Annals of Oncology (2024)
536P A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: Long-term results of JCOG0603
Authors: Y. Kanemitsu, Y. Shimizu, J. Mizusawa, Y. Inaba, A. Takashima, S. Tsukamoto, M. Ohue, K. Komori, A. Shiomi, M. Shiozawa, Y. Suwa, Y. Kinugasa, T. Suto, Y. Kurose, Y. Takii, H. Bando, T. Kobatake, Y. Shimada, H. Katayama, H. Fukuda
Journal: Annals of Oncology (2024)
493P The usefulness of pre-radiotherapy MRI in assessing pseudo-progression in patients with glioblastoma included in first-line clinical trials
Authors: K. Vega Cano, J. Garre, F. Nuñez, M. Gomez, P. Mascaró Baselga, J. Yaringaño Cerna, O. Mirallas, D. Gomez Puerto, G. Molina Lores, C. Auger, C. Lopez, S. Herbera, F. Martinez, D. Marmolejo Castaneda, M. Gonzalez Rodriguez, X. Maldonado, M. Vieito
Journal: Annals of Oncology (2024)
544P Nivolumab plus ipilimumab in microsatellite instability high (MSI)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final survival analysis and prognostic evaluation of GDF-15 in the phase II GERCOR NIPICOL study
Authors: L. Depotte, P. Nay, C. Borg, A. Meurisse, J. Henriques, J. Bennouna, C. de la Fouchardiere, D. Tougeron, T. Mazard, B. Chibaudel, C. Tournigand, D. Vernerey, F. Pigneur, T. André, R. Cohen
Journal: Annals of Oncology (2024)